New cyclodextrin with orphan drug designation: SBECD
ReVision Therapeutics, Inc., a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular
Tag: blindness
A forum for researchers, students and applicants in the field of cyclodextrin technology